Flexion Therapeutics Inc (NASDAQ:FLXN) Institutional Investors 2019 Q3 Sentiment

Flexion Therapeutics Inc (NASDAQ:FLXN) institutional sentiment decreased to 1.24 in 2019 Q3. Its down -0.25, from 1.49 in 2019Q2. The ratio has dropped, as 51 funds increased and opened new holdings, while 41 cut down and sold stock positions in Flexion Therapeutics Inc. The funds in our partner’s database now hold: 32.43 million shares, up from 30.64 million shares in 2019Q2. Also, the number of funds holding Flexion Therapeutics Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 16 Reduced: 25 Increased: 34 New Position: 17.

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company has market cap of $745.55 million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. It currently has negative earnings.

The stock increased 2.84% or $0.54 during the last trading session, reaching $19.53. About 1.45M shares traded or 136.07% up from the average. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has declined 56.61% since December 7, 2018 and is downtrending. It has underperformed by 56.61% the S&P500.

Analysts await Flexion Therapeutics, Inc. (NASDAQ:FLXN) to report earnings on February, 27. They expect $-1.00 earnings per share, up 6.54 % or $0.07 from last year’s $-1.07 per share. After $-1.00 actual earnings per share reported by Flexion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Clearline Capital Lp holds 4.98% of its portfolio in Flexion Therapeutics, Inc. for 797,987 shares. Gagnon Advisors Llc owns 431,306 shares or 3.67% of their US portfolio. Moreover, Gagnon Securities Llc has 2.53% invested in the company for 780,411 shares. The New York-based Kingdon Capital Management L.L.C. has invested 1.59% in the stock. Selz Capital Llc, a New York-based fund reported 340,000 shares.

Since January 1, 0001, it had 2 insider buys, and 0 sales for $46,616 activity.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Ratings Coverage

Ratings analysis reveals 100% of Flexion Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating Flexion Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2400 while the high is $36. The stock’s average target of $29 is 48.49% above today’s ($19.53) share price. FLXN was included in 8 notes of analysts from October 14, 2019. Needham maintained Flexion Therapeutics, Inc. (NASDAQ:FLXN) rating on Monday, October 14. Needham has “Buy” rating and $36 target.

More notable recent Flexion Therapeutics, Inc. (NASDAQ:FLXN) news were published by: Nasdaq.com which released: “Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates – Nasdaq” on November 08, 2019, also Seekingalpha.com with their article: “Flexion up 3% on new Zilretta data – Seeking Alpha” published on July 15, 2019, Seekingalpha.com published: “Flexion Therapeutics: The Time To Buy Is Now – Seeking Alpha” on July 30, 2019. More interesting news about Flexion Therapeutics, Inc. (NASDAQ:FLXN) were released by: Finance.Yahoo.com and their article: “The Daily Biotech Pulse: Cassava Gains On Alzheimer’s Presentation, Bristol-Myers Hikes Dividend – Yahoo Finance” published on December 06, 2019 as well as Finance.Yahoo.com‘s news article titled: “How Should Investors Feel About Flexion Therapeutics, Inc.’s (NASDAQ:FLXN) CEO Pay? – Yahoo Finance” with publication date: August 05, 2019.